IAM Advisory LLC Has $1.45 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

IAM Advisory LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,836 shares of the company’s stock after purchasing an additional 222 shares during the quarter. IAM Advisory LLC’s holdings in Novo Nordisk A/S were worth $1,448,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. International Assets Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the period. DSM Capital Partners LLC raised its holdings in shares of Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at about $98,765,000. Marshall Wace LLP boosted its position in shares of Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $42,017,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Trading Down 5.2 %

NYSE NVO opened at $78.74 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $97.76 and a 200 day simple moving average of $117.23. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The firm has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.